Link to this page
National Cancer Institute Thesaurus
Last uploaded:
February 23, 2024
Jump to:
| Id | http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82385
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82385
|
|---|---|
| Preferred Name | Sonidegib |
| Definitions |
An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.
|
| Synonyms |
Erismodegib
(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-
Smoothened Antagonist LDE225
LDE-225
LDE225
Odomzo
SONIDEGIB
Sonidegib
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label | Sonidegib
|
|---|---|
| Maps_To | Sonidegib
|
| Accepted_Therapeutic_Use_For | locally advanced basal cell carcinoma (BCC)
|
| Legacy Concept Name | Oral_Smoothened_Antagonist_LDE225
|
| NCI_Drug_Dictionary_ID | 641974
|
| Is_Value_For_GDC_Property | |
| PDQ_Closed_Trial_Search_ID | 641974
|
| Preferred_Name | Sonidegib
|
| Display_Name | Sonidegib
|
| Semantic_Type | Pharmacologic Substance
|
| prefixIRI | Thesaurus:C82385
|
| DEFINITION | An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.
|
| UMLS_CUI | C2830069
|
| code | C82385
|
| Chemical_Formula | C26H26F3N3O3
|
| subClassOf | |
| type | |
| CAS_Registry | 956697-53-3
|
| FULL_SYN | Erismodegib
(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-
Smoothened Antagonist LDE225
LDE-225
LDE225
Odomzo
SONIDEGIB
Sonidegib
See more
See less
|
| FDA_UNII_Code | 0RLU3VTK5M
|
| PDQ_Open_Trial_Search_ID | 641974
|
| Contributing_Source |
CTRP
FDA
GDC
HemOnc
|
| Concept_In_Subset |
See more
See less
|
| Has_Target | |
| Has_Salt_Form |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |